BioMarin Pharma (BMRN) Tops Q3 EPS by 13c, Revenue Misses
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
BioMarin Announces Third Quarter 2016 Financial Results
October 27, 2016 4:03 PM EDT- Third Quarter 2016 Total BioMarin Revenues Increase 34% Year over Year to $280 million
- Vimizim Net Product Revenues Increase 25% Year over Year to $81 million in the Third Quarter 2016
- Kuvan Net Product Revenues Increase 42% Year over Year to $91 million in the Third Quarter 2016 Â
 Financial Highlights (in millions of U.S. dollars, except per share data, unaudited)
  Three Months Ended September... More